Please try another search
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
AddLife | 110.60 | 115.10 | 110.60 | -3.30 | -2.90% | 17.41K | 10:34:53 | ||
Arjo | 47.60 | 47.92 | 47.36 | -0.04 | -0.08% | 212.50K | 10:35:39 | ||
Bactiguard Holding AB | 68.80 | 72.20 | 66.80 | -1.60 | -2.27% | 3.16K | 09:28:16 | ||
BICO Group | 45.14 | 46.28 | 44.48 | -0.74 | -1.61% | 56.58K | 10:33:30 | ||
Boule Diagnostics | 10.20 | 10.60 | 9.94 | +0.20 | +2.00% | 156.58K | 10:22:54 | ||
C-Rad | 41.65 | 41.80 | 40.15 | +1.10 | +2.71% | 30.03K | 10:32:38 | ||
CellaVision AB | 264.50 | 269.00 | 244.50 | +21.00 | +8.62% | 44.42K | 10:15:22 | ||
Elekta B | 84.30 | 84.60 | 83.35 | +0.80 | +0.96% | 524.96K | 10:36:55 | ||
Episurf Medical AB | 0.37 | 0.39 | 0.37 | -0.01 | -3.48% | 144.32K | 10:11:42 | ||
Getinge B | 186.1 | 186.6 | 183.5 | +0.9 | +0.49% | 633.48K | 10:36:48 | ||
Immunovia publ AB | 1.22 | 1.38 | 1.04 | -0.27 | -18.12% | 1.42M | 10:36:31 | ||
Ortivus A | 4.380 | 4.380 | 4.020 | +0.120 | +2.82% | 2.91K | 09:00:00 | ||
Ortivus B | 2.530 | 2.560 | 2.490 | +0.020 | +0.80% | 21.63K | 10:07:50 | ||
Q linea | 2.12 | 2.17 | 2.06 | 0.00 | 0.00% | 163.14K | 10:35:02 | ||
RaySearch Labs B | 145.60 | 149.20 | 143.40 | -0.60 | -0.41% | 53.87K | 10:35:52 | ||
Sectra | 237.60 | 239.60 | 236.00 | -1.20 | -0.50% | 35.27K | 10:31:48 | ||
Sedana Medical | 21.90 | 22.80 | 21.75 | -0.70 | -3.10% | 50.25K | 10:13:39 | ||
Senzime | 6.5800 | 6.9300 | 6.4800 | -0.1000 | -1.50% | 286.01K | 10:34:24 | ||
Vitrolife | 185.60 | 188.80 | 185.60 | -2.00 | -1.07% | 17.27K | 10:35:45 | ||
Xvivo Perfusion AB | 405.00 | 408.50 | 402.50 | +3.00 | +0.75% | 38.97K | 10:34:02 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review